Castration resistant prostate cancer, beyond the usual treatment

Poster Session 61

  • Location:
    Room 14b (ICM, Level 1)
  • Chairs:
     T.A. Borkowski, Warsaw (PL)
     S. Egawa, Tokyo (JP)
     A. Necchi, Milan (IT)
  • Aims and objectives of this session

    The treatment Castration Resistant Prostate Cancer has been revolutionised over the years….Understanding its complexity is a major challenge for most urologists. This session will help understand the latest developments in the area.

  • Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.
* 764
Radium-223 (Ra-223) re-treatment (re-tx): Experience from an international, multicenter, prospective study in patients (pts) with castration-resistant prostate cancer and bone metastases (mCRPC)

By: Keizman D.1, Nordquist L.T.2, Mariados N.3, Méndez Vidal M.J.4, Thellenberg Karlsson C.5, Peer A.6, Procopio G.7, Frank S.J.8, Pulkkanen K.9, Severi S.10, Trigo Perez J.M.11, Schwarzenberger P.12, Li R.13, Sartor O.14

Institutes: 1Meir Medical Center, Dept. of Genitourinary Oncology Service, Kfar-Saba, Israel, 2GU Research Network, LLC, Dept. of Medical Oncology, Omaha, Nebraska, United States of America, 3Associated Medical Professionals of New York, PLLC, Dept. of Radiation Oncology, Syracuse, New York, United States of America, 4Hospital Universitario Reina Sofía, Dept. of Medical Oncology, Cordoba, Spain, 5Cancer Center Norrland University, Dept. of Radiation Sciences, Umeå, Sweden, 6Rambam Medical Center, Dept. of Oncology, Haifa, Israel, 7Foundation IRCCS National Cancer Institute, Dept. of Medical Oncology, Milan, Italy, 8Hadassah Hebrew University Medical Center, Dept. of Oncology, Jerusalem, Israel, 9Kuopio University Hospital, Dept. of Oncology, Kuopio, Finland, 10Romagnolo Scientific Institute For The Study and Care of Cancer – IRST IRCCS, Dept. of Nuclear Medicine Therapeutic, Meldola, Italy, 11Hospital Universitario Virgen De La Victoria, Dept. of Medical Oncology, Malaga, Spain, 12Bayer HealthCare, Dept. of Global Clinical Development, Whippany, New Jersey, United States of America, 13Bayer HealthCare, Dept. of Global Research & Development Statistics, Whippany, New Jersey, United States of America, 14Tulane Cancer Center, Dept. of Medicine and Urology, New Orleans, Louisiana, United States of America

* 765
Updated long-term efficacy and safety of androgen receptor inhibitor ODM-201 in phase I/II trial

By: Fizazi K.1, Massard C.1, Bono P.2, Kataja V.3, James N.4, Tammela T.5, Joensuu H.2, Aspegren J.6, Mustonen M.V.6

Institutes: 1Institut Gustave Roussy, Dept. of Cancer Medicine, Villejuif, France, 2Helsinki University Central Hospital, Comprehensive Cancer Center, Helsinki, Finland, 3Kuopio University Hospital, Jyväskylä Central Hospital, Kuopio, Finland, 4Queen Elizabeth Hospital University Hospitals, Birmingham NHS Foundation Trust, Birmingham, Finland, 5Tampere University Hospital, Dept. of Urology, Tampere, Finland, 6Orion Corporation Orion Pharma, Research and Development, Espoo, Finland

Statin use and prostate cancer mortality

By: Benzon Larsen S.1, Skriver C.1, Dehlendorff C.1, Jespersen C.2, Borre M.3, Nørgård M.4, Brasso K.5, Andersen K.K.1, Sørensen H.4, Hallas J.6, Friis S.1

Institutes: 1Danish Cancer Society, Research Centre, Copenhagen, Denmark, 2Viborg Hospital, Dept. of Urology, Viborg, Denmark, 3Aarhus University Hospital, Dept. of Urology, Aarhus, Denmark, 4Aarhus University Hospital, Dept. of Clinical Epidemiology, Aarhus, Denmark, 5Rigshospitalet, Dept. of Urology and Copenhagen Prostate Cancer Centre, Copenhagen, Denmark, 6University of Southern Denmark, Clinical Pharmacology, Odense, Denmark

Testosterone bounce predicts cancer specific survival of prostate cancer patients treated with docetaxel therapy

By: Shuhei K.1, Sakamoto S.2, Yamamoto S.1, Inoue T.1, Nozumi K.1, Chiba K.1, Miyazaki K.1, Atsushi I.1, Nagata M.1

Institutes: 1Yokohama Rosai Hospital, Dept. of Urology, Yokohama City, Kanagawa, Japan, 2Chiba Univ. Hospital, Dept. of Urology, Chiba City, Chiba, Japan

Effect of PSA response on overall and progression-free survival in patients with metastatic castration resistant prostate cancer (mCRPC) treated with cabazitaxel (Caba): The non-interventional study QoLiTime

By: Hammerer P.1, Al-Batran S-E.2, Windemuth-Kieselbach C.3, Hofheinz R-D.4

Institutes: 1Academic Hospital Braunschweig, Dept. of Urology and Uro-Oncology, Braunschweig, Germany, 2Nordwest Hospital, Institute of Clinical Research, Frankfurt, Germany, 3Alcedis GmbH, Dept. of Biometry, Gießen, Germany, 4University Hospital Mannheim, Interdisciplinary Tumor Center, Mannheim, Germany

Initial clinical experience with 177Lu-PSMA I&T radionuclide therapy in patients with metastatic castration-resistant prostate cancer

By: Heck M.M.1, Retz M.1, Rauscher I.2, Scheidhauer K.2, Maurer T.1, Storz E.1, Janssen F.1, D’Alessandria C.2, Wester H.-J.3, Gschwend J.E.1, Schwaiger M.2, Tauber R.1, Eiber M.2

Institutes: 1Klinikum Rechts der Isar der Technischen Universität Muenchen, Dept. of Urology, Munich, Germany, 2Klinikum Rechts der Isar der Technischen Universität Muenchen, Dept. of Nuclear Medicine, Munich, Germany, 3Technische Universität München, Dept. of Pharmaceutical Radiochemistry, Garching, Germany

Hormonal response after long-term androgen suppression in patients with prostate cancer

By: Planas Morin J.1, Celma A.1, Regis L.1, Cuadras M.1, Trilla E.1, Salvador C.1, Placer J.1, Lorente D.1, Carles J.2, Suárez C.2, Morote J.1

Institutes: 1Hospital Universitari Vall d’Hebron, Dept. of Urology, Barcelona, Spain, 2Hospital Universitari Vall d’Hebron, Dept. of Oncology, Barcelona, Spain

Real-world treatment patterns and factors influencing the use of bone-targeted agents (BTAs) in combination with emerging therapeutics in patients with prostate cancer and bone-metastases

By: Body J-J.1, Von Moos R.2, Rider A.3, Bhowmik D.4, Hallworth P.3, Hechmati G.5, Qian Y.4, Gatta F.5

Institutes: 1Chu Brugmann, Dept. Of Medicine, Brussels, Belgium, 2Kantonsspital Graubünden, Dept. of Oncology, Chur, Switzerland, 3Adelphi Real World, Bollington, United Kingdom, 4Amgen Inc., Dept. of Health Economics, Thousand Oaks, United States of America, 5Amgen (Europe) GmbH, Dept. of Health Economics, Zug, Switzerland

Which factors predict overall survival in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate post-docetaxel?

By: Van Praet C.1, Rottey S.2, Van Hende F.3, Pelgrims G.4, Demey W.5, Van Aelst F.6, Wynendaele W.7, Gil T.8, Schatteman P.9, Filleul B.10, Schallier D.11, Machiels J-P.12, Schrijvers D.13, Everaert E.14, D’Hondt L.15, Werbrouck P.16, Vermeij J.17, Mebis J.18, Clausse M.19, Rasschaert M.20, Van Erps J.21, Verheezen J.22, Van Haverbeke J.23, Goeminne J-C.24, Lumen N.1

Institutes: 1Ghent University Hospital, Dept. of Urology, Ghent, Belgium, 2Ghent University Hospital, Dept. of Medical Oncology, Ghent, Belgium, 3Leuven University Hospital, Dept. of Medical Oncology, Leuven, Belgium, 4AZ Turnhout, Dept. of Medical Oncology, Turnhout, Belgium, 5AZ Klina, Dept. of Medical Oncology, Brasschaat, Belgium, 6AZ Delta, Dept. of Medical Oncology, Roeselare, Belgium, 7AZ Imelda, Dept. of Medical Oncology, Bonheiden, Belgium, 8Institut Jules Bordet, Dept. of Medical Oncology, Brussels, Belgium, 9OLV Aalst, Dept. of Urology, Aalst, Belgium, 10Hopital De Jolimont, Dept. of Medical Oncology, Haine Saint Paul, Belgium, 11Brussels University Hospital, Dept. of Medical Oncology, Brussels, Belgium, 12Cliniques Uiversitaires Saint Luc, Dept. of Medical Oncology, Brussels, Belgium, 13Ziekenhuis Netwerk Antwerpen Middelheim, Dept. of Medical Oncology, Antwerp, Belgium, 14AZ Nikolaas, Dept. of Medical Oncology, Sint-Niklaas, Belgium, 15CHU Dinant-Godinne, Dept. of Medical Oncology, Yvoir, Belgium, 16AZ Groeninge, Dept. of Urology, Kortrijk, Belgium, 17Ziekenhuis Netwerk Antwerpen Jan-Palfijn, Dept. of Medical Oncology, Antwerp, Belgium, 18AZ Jessa, Dept. of Medical Oncology, Hasselt, Belgium, 19St Luc Bouge, Dept. of Medical Oncology, Namur, Belgium, 20AZ Monica, Dept. of Medical Oncology, Antwerp, Belgium, 21ASZ Aalst, Dept. of Medical Oncology, Aalst, Belgium, 22AZ Sint-Trudo, Dept. of Medical Oncology, Sint-Truiden, Belgium, 23AZ Sint-Andries, Dept. of Urology, Tielt, Belgium, 24Sainte-Elisabeth, Dept. of Medical Oncology, Namur, Belgium

Abiraterone for castration resistant prostate cancer: Adherence, survival and hospitalization: Analysis of a medical claims database

By: Mohamad Al-Ali B.1, Madersbacher S.1, Berger I.2

Institutes: 1Kaiser-Franz-Josef Spital, Dept. of Urology and Andrology, Vienna, Austria, 2Klinikum Wiener Neustadt, Dept. of Urology and Andrology, Wiener Neustadt, Austria

ARV7 detected by a novel whole-blood RT-PCR assay correlates with outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate (ABI)

By: Todenhöfer T.1, Azad A.2, Gao J.1, Stewart C.1, Eigl B.2, Stenzl A.4, Black P.1, Teich M.3, Joshua A.3, Chi K.2

Institutes: 1University of British Columbia, Vancouver Prostate Centre, Vancouver, Canada, 2British Columbia Cancer Agency, Dept. of Medical Oncology, Vancouver, Canada, 3University of Toronto, Princess Margret Cancer Centre, Toronto, Canada, 4Eberhard-Karls-University, Dept. of Urology, Tübingen, Germany

The phase 3 COU-AA-302 study of abiraterone acetate (AA) in men with chemotherapy (CT)-naïve metastatic castration-resistant prostate cancer (mCRPC): Stratified analysis based on pain, prostate-specific antigen (PSA) and Gleason score (GS)

By: Miller K.1, Carles J.2, Gschwend J.E.3, Van Poppel H.4, Diels J.5, Brookman-May S.D.6

Institutes: 1Charité Berlin, Dept. of Urology, Berlin, Germany, 2Vall D’Hebron University Hospital, Dept. of Medical Oncology, Barcelona, Spain, 3Technical University of Munich, School of Medicine, Munich, Germany, 4Katholieke Universiteit Leuven, Dept. of Urology, Leuven, Belgium, 5Janssen EMEA, HEMAR, Beerse, Belgium, 6Ludwig Maximilians University of Munich, Janssen Research & Development, Munich, Germany